for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Rockwell Medical Inc

RMTI.OQ

Latest Trade

1.95USD

Change

0.10(+5.12%)

Volume

29,720

Today's Range

1.85

 - 

2.00

52 Week Range

1.82

 - 

6.88

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.86
Open
1.86
Volume
29,720
3M AVG Volume
5.79
Today's High
2.00
Today's Low
1.85
52 Week High
6.88
52 Week Low
1.82
Shares Out (MIL)
63.82
Market Cap (MIL)
118.39
Forward P/E
-2.85
Dividend (Yield %)
--

About Rockwell Medical Inc

Rockwell Medical, Inc. is a biopharmaceutical company. The Company is targeting end-stage renal disease and chronic kidney disease with products for the treatment of iron deficiency and hemodialysis. The Company is also a manufacturer of hemodialysis concentrates for dialysis providers and distributors. The Company’s renal drug therapy, Triferic, supports disease management initiatives. Triferic is therapy indicated to replace iron and maintain hemoglobin in hemodialysis patients via dialysate during each dialysis treatment. The Company has developed multiple formulations of Triferic: Dialysate Triferic and Intravenous Triferic (I.V. Triferic). Dialysate Triferic is the therapeutic indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients.

Industry

Biotechnology & Drugs

Contact Info

411 Hackensack Ave Ste 501

https://www.rockwellmed.com/

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-0.390

2017

-0.510

2018

-0.610

2019(E)

-0.650
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.85
Price To Book (MRQ)
3.97
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
6.45
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-92.00
Return on Equity (TTM)
-67.65

Latest News

Latest News

BRIEF-Rockwell Medical Update On Calcitriol New Manufacturing Submission To FDA

* ROCKWELL MEDICAL UPDATE ON CALCITRIOL NEW MANUFACTURING SUBMISSION TO FDA

BRIEF-Rockwell Medical Reports Q4 Loss Per Share $0.18

* ROCKWELL MEDICAL REPORTS FOURTH QUARTER AND YEAR END 2017 RESULTS

BRIEF-Rockwell Medical, Inc. Appoints Two Independent Executives To Board Of Directors

* ROCKWELL MEDICAL, INC. APPOINTS TWO INDEPENDENT AND EXPERIENCED LIFE SCIENCES EXECUTIVES TO BOARD OF DIRECTORS

BRIEF-Richmond Brothers Reports 10 Pct Stake In Rockwell Medical

* RICHMOND BROTHERS INC SAYS ON MARCH 7, RICHMOND BROTHERS AND RICHMOND ENTERED INTO LETTER AGREEMENT WITH ROCKWELL MEDICAL INC

BRIEF-Rockwell Medical Signs License Agreement With Quimica Europea To Commercialize Triferic In Peru

* ROCKWELL MEDICAL SIGNS EXCLUSIVE LICENSE AGREEMENT WITH QUIMICA EUROPEA TO COMMERCIALIZE TRIFERIC IN PERU

BRIEF-Richmond Brothers Says On Nov 22, Entered Into Settlement And Standstill Agreement With Rockwell Medical

* RICHMOND BROTHERS INC SAYS ON NOVEMBER 22, ENTERED INTO SETTLEMENT AND STANDSTILL AGREEMENT WITH ROCKWELL MEDICAL INC - SEC FILING

BRIEF-Rockwell Medical posts Q3 loss of $0.10 per share

* Q3 sales rose 14.1 percent to $14.6 million Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-ROCKWELL MEDICAL SAYS FDA REQUESTS EXTRA TIME TO REVIEW CALCITRIOL SUBMISSION

* ROCKWELL UPDATE ON CALCITRIOL POST-APPROVAL MANUFACTURING SUBMISSION TO FDA

BRIEF-Rockwell files Calcitriol post-approval manufacturing submission with FDA

* Rockwell files Calcitriol post-approval manufacturing submission with FDA

BRIEF-Rockwell Medical updates progress on calcitriol commercial launch

* Rockwell Medical updates progress on calcitriol commercial launch

BRIEF-‍Richmond Brothers responds to Rockwell Medical's board appointment

* Richmond Brothers Inc issues statement in response to Rockwell Medical Inc's appointment of John Cooper to its board of directors

BRIEF-Rockwell Medical appoints John Cooper to board

* Rockwell Medical appoints John G. Cooper to board of directors

BRIEF-Richmond Brothers and Mark H. Ravich issue statement on Rockwell Medical Inc

* Richmond Brothers - "Will not settle for anything less than real and meaningful changes" to Rockwell Medical Board Source text for Eikon: Further company coverage:

BRIEF-Richmond Brothers issues public letter to incumbent directors of Rockwell Medical

* Richmond Brothers Inc issues public letter to incumbent directors of Rockwell Medical Inc.

BRIEF-Rockwell Medical responds to Richmond Group

* Issued statement concerning Richmond Group's filing of an amended schedule 13D with Securities and Exchange Commission

BRIEF-‍Richmond Brothers Inc​ seeks immediate replacement of Rockwell Medical CEO Robert Chioini

* Richmond Brothers Inc says it intends to nominate a competing slate of director candidates for Rockwell Medical Inc

BRIEF-Rockwell Medical Q2 loss per share $0.14

* Q2 sales $13.2 million Source text for Eikon: Further company coverage:

BRIEF-Rockwell Medical, Baxter Healthcare settle arbitration

* Rockwell Medical Inc - on June 23, 2017, co and Baxter Healthcare Corporation settled the arbitration related to claims made by each party

Rockwell Medical shareholders back Ravich for board seat-sources

Shareholders of Rockwell Medical Inc. <RMTI.O> voted investor Mark Ravich onto the company's board of directors, according to people familiar with the matter.

BRIEF-Rockwell Medical says Richmond, Ravich each personally own less than 1 pct of co

* Co "clarifies that David Richmond and Mark Ravich each personally own less than 1% of Rockwell" Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up